Cite
Kim ST, Lee S, Park M, et al. Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Transl Oncol. 2019;12(4):597-601doi: 10.1016/j.tranon.2018.12.009.
Kim, S. T., Lee, S., Park, M., Park, S. H., Park, J. O., Lim, H. Y., Park, Y. S., Kang, W. K., Gangolli, E. A., Shin, H., Kim, K. M., Hollingsworth, S. J., Mortimer, P. G. S., & Lee, J. (2019). Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Translational oncology, 12(4), 597-601. https://doi.org/10.1016/j.tranon.2018.12.009
Kim, Seung Tae, et al. "Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial." Translational oncology vol. 12,4 (2019): 597-601. doi: https://doi.org/10.1016/j.tranon.2018.12.009
Kim ST, Lee S, Park M, Park SH, Park JO, Lim HY, Park YS, Kang WK, Gangolli EA, Shin H, Kim KM, Hollingsworth SJ, Mortimer PGS, Lee J. Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Transl Oncol. 2019 Apr;12(4):597-601. doi: 10.1016/j.tranon.2018.12.009. Epub 2019 Jan 26. PMID: 30695737; PMCID: PMC6348337.
Copy
Download .nbib